open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-11-22
Get Citation

Novel oral anticoagulants — practical aspects. Consensus from Cardiovascular Pharmacotherapy Section of the Polish Cardiac Society

Jarosław D. Kasprzak, Rafał Dąbrowski, Marcin Barylski, Artur Mamcarz, Marcin Wełnicki, Krzysztof J. Filipiak, Piotr Lodziński, Dariusz Kozłowski, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2016.0064
·
Folia Cardiologica 2016;11(5):377-393.

open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-11-22

Abstract

This document is a statement from Cardiovascular Pharmacotherapy Section of the Polish Cardiac Society regarding the practical approach to therapy with novel oral anticoagulants — thrombin antagonists and Xa antagonists, based upon most recent scientific information including European Society of Cardiology guidelines 2016 and recommendations from European Heart Rhythm Association.

Abstract

This document is a statement from Cardiovascular Pharmacotherapy Section of the Polish Cardiac Society regarding the practical approach to therapy with novel oral anticoagulants — thrombin antagonists and Xa antagonists, based upon most recent scientific information including European Society of Cardiology guidelines 2016 and recommendations from European Heart Rhythm Association.

Get Citation

Keywords

NOAC, anticoagulants, atrial fibrillation

About this article
Title

Novel oral anticoagulants — practical aspects. Consensus from Cardiovascular Pharmacotherapy Section of the Polish Cardiac Society

Journal

Folia Cardiologica

Issue

Vol 11, No 5 (2016)

Pages

377-393

Published online

2016-11-22

DOI

10.5603/FC.2016.0064

Bibliographic record

Folia Cardiologica 2016;11(5):377-393.

Keywords

NOAC
anticoagulants
atrial fibrillation

Authors

Jarosław D. Kasprzak
Rafał Dąbrowski
Marcin Barylski
Artur Mamcarz
Marcin Wełnicki
Krzysztof J. Filipiak
Piotr Lodziński
Dariusz Kozłowski
Beata Wożakowska-Kapłon

References (49)
  1. Pruszczyk P, Stępińska J, Banasiak W, et al. New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation. ish Cardiac Society, ish Neurological Society and Working Group on Haemostasis of the ish Society of Haematologists and Transfusiologists consensus statement]. Kardiol Pol. 2012; 70: 979–988.
  2. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
  3. Stępińska J, Wożakowaka-Kapłon B, Pruszczyk P, et al. [Non-vitamin K oral antagonist no more new!]. Kardiol Pol. 2014; 72(9): 854–855.
  4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
  5. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur. Heart J. . 2016.
  6. Heidbuchel H, Verhamme P, Alings M, et al. Advisors:. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
  7. Morimoto T, Crawford B, Wada K, et al. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol. 2015; 66(6): 466–474.
  8. Providência R, Grove EL, Husted S, et al. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014; 134(6): 1253–1264.
  9. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21): 2719–2747.
  10. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013; 144(5): 1555–1563.
  11. Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016; 134(8): 589–598.
  12. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015; 65(13): 1340–1360.
  13. Andreotti F, Rocca B, Husted S, et al. ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015; 36(46): 3238–3249.
  14. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011; 365(21): 2039–2040.
  15. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116–1127.
  16. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost. 2011; 106(1): 156–164.
  17. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011; 9(1): 133–139.
  18. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013; 59(2): 353–362.
  19. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost. 2013; 11 Suppl 1: 122–128.
  20. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. British Journal of Clinical Pharmacology. 2014; 78(4): 908–917.
  21. Rognoni C, Marchetti M, Quaglini S, et al. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014; 34(1): 9–17.
  22. Schulman S, Angerås U, Bergqvist D, et al. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010; 8(1): 202–204.
  23. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015; 373(6): 511–520.
  24. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373(25): 2413–2424.
  25. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371(22): 2141–2142.
  26. Cappato R, Ezekowitz MD, Klein AL, et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
  27. Lip GYH, Merino J, Ezekowitz M, et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J. 2015; 169(5): 597–604.e5.
  28. Coleman CM, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015; 38(6): 731–737.
  29. Kochhäuser S, Khaykin Y, Beardsall J, et al. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. Can J Cardiol. 2014; 30(12): 1541–1546.
  30. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2): 131–136.
  31. Mitamura H, Nagai T, Watanabe A, et al. Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report. J Arrhythm. 2015; 31(4): 226–231.
  32. Pallisgaard JL, Lindhardt TBo, Hansen ML, et al. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study. PLoS One. 2015; 10(10): e0141377.
  33. Johansson AK, Juhlin T, Engdahl J, et al. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? Europace. 2015; 17(10): 1514–1517.
  34. Piccini JP, Stevens SR, Lokhnygina Y, et al. ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013; 61(19): 1998–2006.
  35. Flaker G, Lopes RD, Al-Khatib SM, et al. ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63(11): 1082–1087.
  36. Plitt A, Ezekowitz MD, De Caterina R, et al. ENGAGE AF-TIMI 48 Investigators. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016; 39(6): 345–346.
  37. Coleman CM, Khalaf S, Mould S, et al. Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin. Pacing Clin Electrophysiol. 2015; 38(6): 731–737.
  38. Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol. 2014; 113(8): 1362–1363.
  39. Sen P, Kundu A, Sardar P, et al. Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis. Am J Cardiovasc Drugs. 2016; 16(1): 33–41.
  40. Renda G, Zimarino M, Ricci F, et al. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. Am J Med. 2016; 129(10): 1117–1123.e2.
  41. Lip GYH, Hammerstingl C, Marin F, et al. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2015; 169(4): 464–471.e2.
  42. Lip GYH, Hammerstingl C, Marin F, et al. X-TRA study and CLOT-AF registry investigators. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2015; 169(4): 464–71.e2.
  43. Piotrowski R, Zaborska B, Baran J, et al. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option. Pol Arch Med Wewn. 2016; 126(6): 430–431.
  44. Zylla MM, Pohlmeier M, Hess A, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol. 2015; 115(5): 635–640.
  45. Choo WK, Fraser S, Padfield G, et al. Dabigatran improves the efficiency of an elective direct current cardioversion service. Br J Cardiol. 2014; 21: 29–32.
  46. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012; 14: 528–606.
  47. Sticherling C, Marin F, Birnie D, et al. Document reviewers. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015; 17(8): 1197–1214.
  48. Sardar P, Chatterjee S, Lavie CJ, et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2015; 179: 279–287.
  49. Kristensen SD, Knuuti J, Saraste A, et al. Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014; 35(35): 2383–2431.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl